John M Maris Selected Research

dinutuximab

12/2022	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
1/2021	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
1/2020	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
1/2018	Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.
1/2018	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
1/2018	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
1/2017	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
1/2017	Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
11/2014	Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
9/2010	Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John M Maris Research Topics

Disease

189	Neoplasms (Cancer) 10/2022 - 08/2003
178	Neuroblastoma 12/2022 - 04/2003
13	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2020 - 01/2008
13	Leukemia 12/2015 - 06/2008
12	Ewing Sarcoma (Sarcoma, Ewing) 01/2019 - 06/2008
10	Rhabdomyosarcoma 01/2021 - 06/2008
9	Osteosarcoma (Osteogenic Sarcoma) 01/2020 - 06/2008
7	Glioblastoma (Glioblastoma Multiforme) 02/2021 - 06/2008
7	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2009
7	Sarcoma (Soft Tissue Sarcoma) 01/2019 - 11/2003
6	Rhabdoid Tumor (Rhabdoid Tumors) 12/2019 - 05/2008
5	Wilms Tumor (Wilm's Tumor) 01/2020 - 05/2008
5	Neutropenia 01/2017 - 06/2004
4	Hypotension (Low Blood Pressure) 12/2022 - 11/2010
4	Hypersensitivity (Allergy) 12/2022 - 09/2010
4	Brain Neoplasms (Brain Tumor) 12/2020 - 05/2008
4	Hypoxia (Hypoxemia) 01/2020 - 11/2010
4	Residual Neoplasm 10/2019 - 12/2011
4	Ganglioneuroblastoma 01/2017 - 07/2008
3	Fever (Fevers) 12/2022 - 01/2017
3	Carcinogenesis 01/2020 - 12/2015
3	Pain (Aches) 01/2017 - 09/2010
3	Thrombocytopenia (Thrombopenia) 01/2017 - 06/2004
3	Ganglioneuroma 03/2013 - 07/2008
3	Carcinoma (Carcinomatosis) 02/2013 - 11/2003
2	Hypertrophy 01/2021 - 09/2018
2	Lung Neoplasms (Lung Cancer) 01/2021 - 02/2013
2	Glioma (Gliomas) 01/2021 - 05/2017
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 05/2016

Drug/Important Bio-Agent (IBA)

38	N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA 01/2017 - 12/2007
29	Proteins (Proteins, Gene)FDA Link 10/2022 - 04/2003
21	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2003
18	3-Iodobenzylguanidine (Iobenguane)IBA 11/2021 - 10/2003
16	Biological ProductsIBA 03/2020 - 08/2003
15	Phosphotransferases (Kinase)IBA 04/2020 - 11/2005
10	dinutuximabIBA 12/2022 - 09/2010
10	Irinotecan (Camptosar)FDA LinkGeneric 11/2021 - 03/2009
10	Biomarkers (Surrogate Marker)IBA 10/2021 - 11/2005
10	Pharmaceutical PreparationsIBA 03/2020 - 06/2008
10	Isotretinoin (Accutane)FDA LinkGeneric 10/2019 - 01/2009
9	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2007
9	Messenger RNA (mRNA)IBA 01/2020 - 04/2003
8	Interleukin-2 (IL2)IBA 12/2022 - 09/2010
8	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 09/2010
8	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 03/2009
8	Protein Isoforms (Isoforms)IBA 01/2017 - 08/2003
7	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 02/2013
7	LigandsIBA 01/2018 - 12/2009
6	Vincristine (Oncovin)FDA LinkGeneric 11/2021 - 12/2007
6	Oncogene Proteins (Oncogene Protein)IBA 04/2021 - 04/2003
6	N-Myc Proto-Oncogene ProteinIBA 01/2021 - 03/2013
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 12/2006
5	Chimeric Antigen ReceptorsIBA 10/2022 - 12/2015
5	EnzymesIBA 04/2021 - 11/2003
5	ChromatinIBA 01/2020 - 01/2019
5	MLN 8237IBA 12/2018 - 07/2010
5	Anaplastic Lymphoma KinaseIBA 01/2018 - 10/2008
5	ABT751IBA 06/2014 - 08/2006
5	Sirolimus (Rapamycin)FDA Link 05/2012 - 09/2006
4	NucleotidesIBA 01/2022 - 01/2018
4	CytokinesIBA 01/2022 - 06/2013
4	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 11/2017
4	Aurora Kinase AIBA 04/2020 - 11/2011
4	CatecholaminesIBA 11/2017 - 09/2004
4	Monoclonal AntibodiesIBA 01/2017 - 09/2010
4	Antineoplastic Agents (Antineoplastics)IBA 10/2016 - 11/2003
4	Angiogenesis InhibitorsIBA 11/2014 - 04/2005
3	Immune Checkpoint InhibitorsIBA 02/2021 - 12/2019
3	adavosertibIBA 01/2020 - 01/2013
3	lorukafusp alfaIBA 10/2019 - 11/2010
3	ElementsIBA 01/2018 - 12/2015
3	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 11/2017 - 01/2012
3	Melphalan (Alkeran)FDA LinkGeneric 01/2016 - 01/2006
3	Topotecan (Hycamtin)FDA LinkGeneric 11/2013 - 05/2010
3	GSK923295IBA 02/2013 - 04/2010
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2012 - 04/2005
3	lestaurtinibIBA 12/2011 - 03/2010
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2011 - 11/2005
3	Tyrosine (L-Tyrosine)FDA Link 11/2011 - 11/2005
3	OligonucleotidesIBA 06/2006 - 04/2003
2	GlypicansIBA 10/2022 - 01/2021
2	AntigensIBA 10/2022 - 01/2019
2	Mitochondrial DNA (mtDNA)IBA 01/2022 - 12/2020
2	Vorinostat FDA Link 11/2021 - 09/2009
2	PolyaminesIBA 04/2021 - 08/2011
2	B7-H1 AntigenIBA 02/2021 - 10/2017
2	EpitopesIBA 01/2021 - 12/2015
2	ORALIT (ORS)IBA 12/2020 - 05/2017
2	AntibodiesIBA 03/2020 - 05/2012
2	RadiopharmaceuticalsIBA 01/2020 - 05/2012
2	Histones (Histone)IBA 01/2020 - 01/2017
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020 - 01/2015

Therapy/Procedure

87	Therapeutics 12/2022 - 10/2003
22	Immunotherapy 12/2022 - 09/2010
21	Drug Therapy (Chemotherapy) 10/2019 - 07/2003
7	Radiotherapy 01/2017 - 10/2003
6	Stem Cell Transplantation 04/2015 - 01/2006
5	Chemoradiotherapy 10/2017 - 01/2009
4	Induction Chemotherapy 01/2019 - 04/2013
3	Duration of Therapy 12/2019 - 07/2010